Concord Biotech Q2 Results FY27: Revenue Up 25.1% to Rs 309.07 Cr, PAT Rs 69.57 Cr
- October 28, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Concord Biotech Q2 Results FY27 were declared on 27 October 2026 and cover the July to September 2026 quarter on a consolidated basis. Revenue rose 25.1% YoY to Rs 309.07 Cr, while net profit increased 10.32% YoY to Rs 69.57 Cr. These quarterly results show YoY growth in both lines, with revenue growing faster than net profit, and Operating Profit stood at Rs 104.38 Cr.
Concord Biotech Ltd (CONCORDBIO) Q2 Results FY27 announced on 27 October 2026, covering the company’s financial performance for the July to September quarter. The consolidated results show revenue of Rs 309.07 Cr against Rs 247.06 Cr in the same quarter last year, and net profit of Rs 69.57 Cr against Rs 63.06 Cr. Concord Biotech Q2 Results FY27 therefore arrive with a results date of 27 October 2026 and a clear lead for revenue over profit.
This results analysis of Concord Biotech Q2 Results covers the financial highlights, the business drivers, the outlook and the risks. It begins with the Financial Highlights table that follows, where revenue, Operating Profit and net profit sit side by side with the same quarter of last year.
Click Here – Get Free Investment Predictions
Concord Biotech Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 309.07 Cr | Rs 247.06 Cr | +25.1% YoY |
| Operating Profit | Rs 104.38 Cr | Rs 88.49 Cr | +17.96% YoY |
| Net Profit (PAT) | Rs 69.57 Cr | Rs 63.06 Cr | +10.32% YoY |
Source: company filing for Concord Biotech Q2 Results FY27, 27 October 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Concord Biotech Q2 Results: What Stands Out
- Revenue: Revenue grew to Rs 309.07 Cr from Rs 247.06 Cr, a 25.1% rise on the same quarter of the previous year.
- Net profit: Net profit rose 10.32% to Rs 69.57 Cr from Rs 63.06 Cr, so YoY growth in profit trailed the revenue rise.
- Operating Profit: Operating Profit reached Rs 104.38 Cr from Rs 88.49 Cr, a 17.96% increase that sits between the revenue and net profit movements.
- Margin and returns: Net profit margin narrowed to 22.5% from 25.5%, and the full-year return measures declined, which the risks section covers later.
- Concord Biotech Q2 Results FY27: The performance analysis that follows explains how these three lines moved against each other.
Concord Biotech Q2 Results FY27: Performance Analysis
Concord Biotech Q2 Results FY27 show that revenue moved up 25.1% to Rs 309.07 Cr, Operating Profit moved up 17.96% to Rs 104.38 Cr and net profit moved up 10.32% to Rs 69.57 Cr. Every line grew, and the gap between the three growth rates is the main feature of these quarterly results.
Revenue was built on a base of Rs 247.06 Cr a year earlier, while Operating Profit grew from Rs 88.49 Cr and net profit grew from Rs 63.06 Cr. YoY growth therefore ranks revenue first, Operating Profit second and net profit third, a ranking that the consolidated results table above makes visible at a glance.
Readers who follow the Univest Screener can use this Concord Biotech Q2 Results data as a clean base for tracking later disclosures, including whether revenue keeps growing faster than net profit. The next step in the results analysis is to look at the business factors disclosed for the quarter.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue and Net Profit Growth – The results analysis points to three business factors, and the first is growth itself. Revenue grew 25.1% year on year to Rs 309.07 Cr in the latest quarter, and net profit rose 10.3% year on year to Rs 69.57 Cr alongside it.
Return on Capital Employed – Return on capital employed was 18.04% in FY26. This full-year measure gives context to the quarterly results, because it describes the returns earned on the capital the company has put to work over the last financial year.
Almost Debt Free Position – The company is almost debt free, with a debt-to-assets ratio of 0.00 in FY26. That position frames Concord Biotech Q2 Results FY27, since the quarter’s net profit of Rs 69.57 Cr was reported by a company carrying almost no debt against its assets.
FY27 Outlook After Concord Biotech Q2 Results
The FY27 outlook rests on the quarters still to be reported, and on sector conditions as they are disclosed. The figures behind Concord Biotech Q2 Results FY27 describe the current quarter only, so this results analysis does not stretch them into any full-year revenue or net profit number.
Net profit of Rs 69.57 Cr is the base against which later quarters will be read, and readers can follow each new filing on the Univest app as it is declared. The risks that could shape those later quarters are set out next.
Key Risks to Watch After Concord Biotech Q2 Results FY27
Narrower Net Profit Margin
Net profit margin narrowed to 22.5% from 25.5% in the comparison quarter, so net profit grew 10.32% while revenue grew 25.1%. Later quarters will show whether that gap between the two growth rates stays or closes.
Lower Return on Equity
Return on equity declined to 13.54% in FY26 from 22.26% in FY25. This full-year measure sits beside the quarterly YoY growth in Concord Biotech Q2 Results FY27, and it is worth tracking in later filings alongside net profit.
Lower Return on Capital Employed
Return on capital employed declined to 18.04% in FY26 from 29.62% in FY25, so the capital efficiency measure moved down even though revenue grew in this quarter and the company stayed almost debt free.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Concord Biotech Q2 Results FY27 show revenue up 25.1% to Rs 309.07 Cr, net profit up 10.32% to Rs 69.57 Cr and Operating Profit at Rs 104.38 Cr. These consolidated results and quarterly results give a clear picture of how the three lines moved, and readers can revisit the Concord Biotech Q2 Results data as new disclosures arrive. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Concord Biotech Q2 Results FY27
What are Concord Biotech Q2 Results FY27?
Ans. Concord Biotech Q2 Results FY27 are the consolidated quarterly results for July to September 2026, showing revenue of Rs 309.07 Cr and net profit of Rs 69.57 Cr, as the Quick Answer box summarises.
What is the results date for Concord Biotech Q2 Results FY27?
Ans. The results date was 27 October 2026, when the company declared its consolidated numbers, which means the Financial Highlights table reflects that filing for the July to September quarter.
What revenue was reported in Concord Biotech Q2 Results FY27?
Ans. Concord Biotech reported revenue of Rs 309.07 Cr in the quarter, compared with Rs 247.06 Cr a year earlier, which is the starting point of the Performance Analysis section.
What net profit was reported in Concord Biotech Q2 Results FY27?
Ans. Net profit came in at Rs 69.57 Cr against Rs 63.06 Cr in the same quarter last year, while the Key Takeaways section places that figure beside revenue and Operating Profit.
How much YoY growth did revenue show in Concord Biotech Q2 Results FY27?
Ans. Revenue showed YoY growth of 25.1% in the quarter, alongside net profit growth of 10.32%, so the Performance Analysis section ranks revenue growth ahead of profit growth.
Did net profit rise or fall in Concord Biotech Q2 Results?
Ans. Net profit rose 10.32% YoY to Rs 69.57 Cr in Concord Biotech Q2 Results, compared with Rs 63.06 Cr a year earlier, which is why the Key Risks section looks at the narrower margin.
What was the Operating Profit in Concord Biotech Q2 Results FY27?
Ans. Operating Profit was Rs 104.38 Cr against Rs 88.49 Cr a year earlier, a rise of 17.96%, which means it grew faster than net profit and slower than revenue.
Are Concord Biotech Q2 Results consolidated results or standalone results?
Ans. Consolidated is the basis used in Concord Biotech Q2 Results, so the revenue and net profit figures reflect consolidated results, and the Financial Highlights table follows the same basis.
What business factors shaped Concord Biotech Q2 Results FY27?
Ans. The disclosed factors are revenue growth of 25.1%, net profit growth of 10.3%, return on capital employed of 18.04% in FY26 and an almost debt free position, detailed in Key Business Factors.
What are the key risks after Concord Biotech Q2 Results FY27?
Ans. The listed risks are a net profit margin of 22.5% against 25.5%, return on equity of 13.54% against 22.26%, and return on capital employed of 18.04% against 29.62%, as covered in Key Risks.
What is the outlook after Concord Biotech Q2 Results?
Ans. FY27 full-year results will depend on the quarters still to be reported, so the outlook rests on later filings, while the Outlook section uses the current net profit of Rs 69.57 Cr as its base.
Where can I find the complete Concord Biotech Q2 Results FY27 data?
Ans. The complete figures sit in the Financial Highlights table of this article, while the Univest Screener lets readers follow later filings, as mentioned in the Performance Analysis section.
